An international working group of clinicians and pathologists met in 2003 under the auspices of the International Society of Nephrology (ISN) and the Renal Pathology Society (RPS) to revise and update the 1982 and 1995 World Health Organization classification of lupus glomerulonephritis. This article compares and contrasts the ISN/RPS classification and the antecedent World Health Organization classifications. Although systemic lupus erythematosus is the prototypical systemic immune-complex disease, several non-immune-complex mechanisms of glomerular injury and dysfunction have been proposed, and this article summarizes the evidence supporting the pathogenic mechanisms of lupus vasculitis, glomerular capillary thrombosis, and lupus podocytopathy. The most significant and controversial feature of the ISN/RPS classification is the separation of diffuse glomerulonephritis into separate classes with either segmental (class IV-S) or global (class IV-G) lesions. Several groups have tested the prognostic significance of this separation, and this article discusses the implications of these studies for the ISN/RPS classification.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.semnephrol.2006.09.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Urinary congophilia as a predictive biomarker of lupus nephritis in pregnant and non-pregnant women with systemic lupus erythematosus.
Lupus
January 2025
Mansoura Nephrology and Dialysis Unit, Mansoura University, Mansoura, Egypt.
Background: Endoplasmic reticulum stress with protein misfolding has been introduced as a key pathogenetic mechanism in lupus nephritis (LN). Pregnancy is thought to exaggerate proteostasis, which leads to the accumulation of potentially pathogenic misfolded proteins in the urine, serum, and placenta particularly in women with preeclampsia. The detection of misfolded proteins is made using Congo red stain, which is referred to as congophilia.
View Article and Find Full Text PDFArticle Synopsis
- The study aims to investigate the relationship between clinical and morphological features of kidney issues in patients with systemic lupus erythematosus (SLE).
- A total of 62 patients with lupus nephritis (LN) were examined, revealing that most were female and had a median age of SLE onset around 23 years; various extrarenal symptoms were noted alongside kidney involvement.
- The findings showed significant variation in LN presentations, emphasizing the necessity of kidney biopsies for accurate classification, as similar symptoms like proteinuria were observed across different LN classes.
Do we really need cyclophosphamide for lupus nephritis?
Pediatr Nephrol
November 2024
Department of Pediatrics, University of Colorado, Denver, CO, USA.
A 14-year-old patient presents with hematuria and proteinuria. Clinical evaluation reveals a positive anti-nuclear antibody titer, positive anti-double stranded DNA antibody and hypocomplementemia. Systemic lupus erythematosus (SLE) is diagnosed based on the 2019 EULAR/ACR (European League Against Rheumatism/American College of Rheumatology) classification criteria (Aringer et al.
View Article and Find Full Text PDFArticle Synopsis
- * A case study describes a 10-year-old girl diagnosed with class IV lupus nephritis (LN) and associated complications, including thrombotic microangiopathy (TMA) and severe hypertension.
- * Renal VL are often neglected in SLE assessments, which can impact treatment; however, the PLASMIC score can help manage TMA in LN patients, highlighting the importance of evaluating these lesions.
Infliximab biosimilar-induced lupus nephritis: A case report.
Mod Rheumatol Case Rep
December 2023
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
We present a case of microhematuria, proteinuria and hypocomplementemia which developed in a 55-year-old female who was being treated with an infliximab biosimilar for rheumatoid arthritis. Renal biopsy showed lupus nephritis (ISN/RPS classification class IV + V). Treatment with the infliximab biosimilar was discontinued, and treatment with prednisolone, hydroxychloroquine and abatacept was started, resulting in clinical remission of lupus nephritis and RA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!